Aug 19 (Reuters) - PTC Therapeutics Inc PTCT.O:
PTC THERAPEUTICS RECEIVES COMPLETE RESPONSE LETTER FOR VATIQUINONE NDA
PTC THERAPEUTICS INC - FDA REQUIRES ADDITIONAL STUDY FOR VATIQUINONE NDA RESUBMISSION
PTC THERAPEUTICS: PLANS TO MEET WITH FDA TO DISCUSS POTENTIAL STEPS TO ADDRESS ISSUES RAISED IN CRL
PTC THERAPEUTICS INC: FDA STATED IN CRL THAT SUBSTANTIAL EVIDENCE OF EFFICACY WAS NOT DEMONSTRATED FOR VATIQUINONE